Surprisingly, it has just recently been reported in two independent clinical trials (NCT03050216 and NCT01898793) that systemic administration of N-803 promoted host CD8 T cell activation, accelerating donor NK cell rejection and, thus, limiting the efficacy of haploidentical NK cell therapy in relapsed/refractory AML patients when compared to IL-2 administration [176]. This evidence concerns the gene IL2 and acute myeloid leukemia.